1. Impact of COVID-19 in the incidence of venous thromboembolism (VTE) and clinical outcomes in cancer patients: a cohort study.
- Author
-
López-Jiménez C, Gutiérrez A, Juliao Caamaño DS, Soto Alsar J, Catoya Villa JL, Blanco Abad C, Morón B, Ortega Morán L, Martín M, and Muñoz Martín AJ
- Subjects
- Humans, Female, Male, Incidence, Retrospective Studies, Middle Aged, Aged, Risk Factors, SARS-CoV-2, Adult, Aged, 80 and over, Cohort Studies, Obesity complications, COVID-19 complications, COVID-19 epidemiology, COVID-19 mortality, Venous Thromboembolism epidemiology, Venous Thromboembolism etiology, Neoplasms epidemiology, Neoplasms complications
- Abstract
Purpose: To determine the incidence of VTE and clinical outcomes in a cohort of cancer patients and COVID-19 infection, and to establish possible predictive factors of VTE., Methods/patients: A single-center retrospective cohort study was performed to determine the incidence of VTE and mortality in 118 cancer patients with SARS-CoV-2 infection from March to August 2020. We calculated individual Khorana Risk and CATS-MICA scores in order to evaluate their utility to identify risk of VTE or death. Continuous variables were compared using Wilcoxon or Student's T test, and categorical variables were compared using the Chi-Square or Fisher's exact text among patients with and without VTE. A Log-Rank test was performed to detect mortality differences between the groups., Results: A total of 118 patients were included. VTE global incidence was 4.2% (n = 5), and mortality 25.4% (n = 30). Obesity (p = 0.05), recent chemotherapy (p = 0.049) and use of steroids (p = 0.006) were related to higher risk of VTE in the univariate analysis, although they were not confirmed in the multivariate analysis as independent risk factors. Statistically significant differences in all-cause, COVID-19-related and cancer-related mortality according to the Khorana risk score (KRS) were observed. CATS-MICA score (CMS) also showed statistically significant differences in mortality between low- and high-risk patients. Prediction of risk of VTE development with these scores showed a tendency towards significance., Conclusions: In this cohort, VTE incidence was similar to previously reported in the general population with SARS-CoV-2 infection. KRS was associated with overall and specific-cause mortality, and might be a useful prognostic tool in this setting., Competing Interests: Declarations. Conflict of interest: MMAJ declares consulting or advisory role: Celgene, Sanof, Pfzer, Bristol-Myers Squibb, LEO Pharma, Daiichi Sankyo, Bayer, Halozyme; speakers’ bureau: Rovi; research funding: Sanof, LEO Pharma and patents, royalties, other intellectual property: risk assessment model in venous thromboembolism in patients with cancer. OML has participated as speaker in meetings sponsored by Leo Pharma, Rovi, Menarivi, Servier. MM reports honoraria from SeaGen, Lilly, AstraZeneca, Pfizer, Daiichi Sankyo, Roche; consulting fees from Roche, Novartis, AstraZeneca, Daiichi Sankyo, SeaGen, Lilly, Sanofi; advisory board of Novartis and holds leadership roles in GEICAM (Board of Directors), TRIO. LJC, GA, JDS, SAJ, CVJL, BAC and MB declare no conflict of interests. Ethical approval: The study has been performed in accordance with the ethical standards of the Declaration of Helsinki and its later amendments. This study is an observational, non-interventionist trial. Informed consent: Signed informed consent was obtained from all the patients., (© 2024. The Author(s), under exclusive licence to Federación de Sociedades Españolas de Oncología (FESEO).)
- Published
- 2025
- Full Text
- View/download PDF